Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

William G Wierda; Andrew Rawstron; Florence Cymbalista; Xavier Badoux; Davide Rossi; Jennifer R Brown; Alexander Egle; Virginia Abello; Eduardo Cervera Ceballos; Yair Herishanu; Stephen P Mulligan; Carsten U Niemann; Colin P Diong; Teoman Soysal; Ritsuro Suzuki; Hoa T T Tran; Shang-Ju Wu; Carolyn Owen; Stephan Stilgenbauer; Paolo Ghia; Peter Hillmen

doi:10.1038/s41375-021-01241-1

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

William G Wierda
, Andrew Rawstron
, Florence Cymbalista
, Xavier Badoux
, Davide Rossi
, Jennifer R Brown
, Alexander Egle (Co-author)
, Virginia Abello
, Eduardo Cervera Ceballos
, Yair Herishanu
, Stephen P Mulligan
, Carsten U Niemann
, Colin P Diong
, Teoman Soysal
, Ritsuro Suzuki
, Hoa T T Tran
, Shang-Ju Wu
, Carolyn Owen
, Stephan Stilgenbauer
, Paolo Ghia

Peter Hillmen

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Review article › peer-review

63 Citations (Web of Science)

Original language	English
Pages (from-to)	3059-3072
Journal	LEUKEMIA
Volume	35
Issue number	11
DOIs	https://doi.org/10.1038/s41375-021-01241-1
Publication status	Published - 2021

Keywords

PREVIOUSLY UNTREATED PATIENTS
OPEN-LABEL
FLOW-CYTOMETRY
INDEPENDENT PREDICTOR
RITUXIMAB REGIMEN
1ST-LINE THERAPY
PROGRESSION-FREE
FREE SURVIVAL
END-POINT
PHASE-II

Access to Document

10.1038/s41375-021-01241-1

Cite this

Wierda, W. G., Rawstron, A., Cymbalista, F., Badoux, X., Rossi, D., Brown, J. R., Egle, A., Abello, V., Cervera Ceballos, E., Herishanu, Y., Mulligan, S. P., Niemann, C. U., Diong, C. P., Soysal, T., Suzuki, R., Tran, H. T. T., Wu, S.-J., Owen, C., Stilgenbauer, S., ... Hillmen, P. (2021). Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. LEUKEMIA , 35(11), 3059-3072. https://doi.org/10.1038/s41375-021-01241-1

Wierda, William G ; Rawstron, Andrew ; Cymbalista, Florence et al. / Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. In: LEUKEMIA 2021 ; Vol. 35, No. 11. pp. 3059-3072.

@article{f5d7378482e746db92ea9643222e85b3,

title = "Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.",

keywords = "PREVIOUSLY UNTREATED PATIENTS, OPEN-LABEL, FLOW-CYTOMETRY, INDEPENDENT PREDICTOR, RITUXIMAB REGIMEN, 1ST-LINE THERAPY, PROGRESSION-FREE, FREE SURVIVAL, END-POINT, PHASE-II",

author = "Wierda, \{William G\} and Andrew Rawstron and Florence Cymbalista and Xavier Badoux and Davide Rossi and Brown, \{Jennifer R\} and Alexander Egle and Virginia Abello and \{Cervera Ceballos\}, Eduardo and Yair Herishanu and Mulligan, \{Stephen P\} and Niemann, \{Carsten U\} and Diong, \{Colin P\} and Teoman Soysal and Ritsuro Suzuki and Tran, \{Hoa T T\} and Shang-Ju Wu and Carolyn Owen and Stephan Stilgenbauer and Paolo Ghia and Peter Hillmen",

note = "Egle: Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Salzburg, Austria",

year = "2021",

doi = "10.1038/s41375-021-01241-1",

language = "English",

volume = "35",

pages = "3059--3072",

journal = "LEUKEMIA ",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

Wierda, WG, Rawstron, A, Cymbalista, F, Badoux, X, Rossi, D, Brown, JR, Egle, A, Abello, V, Cervera Ceballos, E, Herishanu, Y, Mulligan, SP, Niemann, CU, Diong, CP, Soysal, T, Suzuki, R, Tran, HTT, Wu, S-J, Owen, C, Stilgenbauer, S, Ghia, P & Hillmen, P 2021, 'Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.', LEUKEMIA , vol. 35, no. 11, pp. 3059-3072. https://doi.org/10.1038/s41375-021-01241-1

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. / Wierda, William G; Rawstron, Andrew; Cymbalista, Florence et al.
In: LEUKEMIA , Vol. 35, No. 11, 2021, p. 3059-3072.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

AU - Wierda, William G

AU - Rawstron, Andrew

AU - Cymbalista, Florence

AU - Badoux, Xavier

AU - Rossi, Davide

AU - Brown, Jennifer R

AU - Egle, Alexander

AU - Abello, Virginia

AU - Cervera Ceballos, Eduardo

AU - Herishanu, Yair

AU - Mulligan, Stephen P

AU - Niemann, Carsten U

AU - Diong, Colin P

AU - Soysal, Teoman

AU - Suzuki, Ritsuro

AU - Tran, Hoa T T

AU - Wu, Shang-Ju

AU - Owen, Carolyn

AU - Stilgenbauer, Stephan

AU - Ghia, Paolo

AU - Hillmen, Peter

N1 - Egle: Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Salzburg, Austria

PY - 2021

Y1 - 2021

KW - PREVIOUSLY UNTREATED PATIENTS

KW - OPEN-LABEL

KW - FLOW-CYTOMETRY

KW - INDEPENDENT PREDICTOR

KW - RITUXIMAB REGIMEN

KW - 1ST-LINE THERAPY

KW - PROGRESSION-FREE

KW - FREE SURVIVAL

KW - END-POINT

KW - PHASE-II

U2 - 10.1038/s41375-021-01241-1

DO - 10.1038/s41375-021-01241-1

M3 - Review article

C2 - 34168283

SN - 0887-6924

VL - 35

SP - 3059

EP - 3072

JO - LEUKEMIA

JF - LEUKEMIA

IS - 11

ER -

Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. LEUKEMIA . 2021;35(11):3059-3072. doi: 10.1038/s41375-021-01241-1